cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5439/1975391
title: sashevis (b1)

description: The shortwave array spectroradiometer—hemispheric (SASHE) uses a hemispheric spectralon diffuser and rotating shadowband similar to the MFRSR and RSS instruments, so it also provides spectrally resolved, direct-normal, diffuse-horizontal, and total-horizontal irradiances, and can be calibrated in situ via Langley regression. The SASHE incorporates two Avantes fiber-coupled spectroradiometers (Avaspec ULS 2048 CCD and Avaspec NIR256-1.7) for visible and near-infrared detection in the wavelength range 350-1700 nm. The spectral resolution is 2.4 nm for the ULS 2048 CCD and 6 nm for the NIR256-1.7. Like the SWS and SASZE, an external collector mounted outdoors is connected via fiber-optic cable to a pair of spectroradiometers housed indoors, so the entire spectral range is measured simultaneously for both spectroradiometers. For the typical shadowband measurement, the spectroradiometers are operated with one measurement per second, but the entire shadowband sequence takes about 20 seconds, so this is the measurement interval for the irradiances. The SASHE operating sequence is configurable and supports alternate programmed sequences as a function of solar zenith angle. For example, it currently employs different sequences for high sun angles, low sun angles, and twilight conditions when the sun is below the horizon but the sky is not yet fully dark. It also includes a mode where visible spectra are collected rapidly while the band is moved over a range of near-sun angles to characterize the forward-scattered radiation. The SASHE data are preliminarily calibrated through comparison with calibrated lamps. The accuracy of irradiance produced by the SASHE is expected to be better than ±5%, which includes calibration and instrument stability errors. Under suitably uniform atmospheric conditions, higher calibration accuracy and precisions (±1%) can be obtained when the responsivity is tied to the solar extraterrestrial irradiance via Langley regression plots. This approach is recommended when high-precision measurements of optical depth are required.
DOI: 10.5439/1975392
title: sashemfr (b1)

description: The shortwave array spectroradiometer—hemispheric (SASHE) uses a hemispheric spectralon diffuser and rotating shadowband similar to the MFRSR and RSS instruments, so it also provides spectrally resolved, direct-normal, diffuse-horizontal, and total-horizontal irradiances, and can be calibrated in situ via Langley regression. The SASHE incorporates two Avantes fiber-coupled spectroradiometers (Avaspec ULS 2048 CCD and Avaspec NIR256-1.7) for visible and near-infrared detection in the wavelength range 350-1700 nm. The spectral resolution is 2.4 nm for the ULS 2048 CCD and 6 nm for the NIR256-1.7. Like the SWS and SASZE, an external collector mounted outdoors is connected via fiber-optic cable to a pair of spectroradiometers housed indoors, so the entire spectral range is measured simultaneously for both spectroradiometers. For the typical shadowband measurement, the spectroradiometers are operated with one measurement per second, but the entire shadowband sequence takes about 20 seconds, so this is the measurement interval for the irradiances. The SASHE operating sequence is configurable and supports alternate programmed sequences as a function of solar zenith angle. For example, it currently employs different sequences for high sun angles, low sun angles, and twilight conditions when the sun is below the horizon but the sky is not yet fully dark. It also includes a mode where visible spectra are collected rapidly while the band is moved over a range of near-sun angles to characterize the forward-scattered radiation. The SASHE data are preliminarily calibrated through comparison with calibrated lamps. The accuracy of irradiance produced by the SASHE is expected to be better than ±5%, which includes calibration and instrument stability errors. Under suitably uniform atmospheric conditions, higher calibration accuracy and precisions (±1%) can be obtained when the responsivity is tied to the solar extraterrestrial irradiance via Langley regression plots. This approach is recommended when high-precision measurements of optical depth are required.
DOI: 10.5439/1975393
title: sashenir (b1)

description: The shortwave array spectroradiometer—hemispheric (SASHE) uses a hemispheric spectralon diffuser and rotating shadowband similar to the MFRSR and RSS instruments, so it also provides spectrally resolved, direct-normal, diffuse-horizontal, and total-horizontal irradiances, and can be calibrated in situ via Langley regression. The SASHE incorporates two Avantes fiber-coupled spectroradiometers (Avaspec ULS 2048 CCD and Avaspec NIR256-1.7) for visible and near-infrared detection in the wavelength range 350-1700 nm. The spectral resolution is 2.4 nm for the ULS 2048 CCD and 6 nm for the NIR256-1.7. Like the SWS and SASZE, an external collector mounted outdoors is connected via fiber-optic cable to a pair of spectroradiometers housed indoors, so the entire spectral range is measured simultaneously for both spectroradiometers. For the typical shadowband measurement, the spectroradiometers are operated with one measurement per second, but the entire shadowband sequence takes about 20 seconds, so this is the measurement interval for the irradiances. The SASHE operating sequence is configurable and supports alternate programmed sequences as a function of solar zenith angle. For example, it currently employs different sequences for high sun angles, low sun angles, and twilight conditions when the sun is below the horizon but the sky is not yet fully dark. It also includes a mode where visible spectra are collected rapidly while the band is moved over a range of near-sun angles to characterize the forward-scattered radiation. The SASHE data are preliminarily calibrated through comparison with calibrated lamps. The accuracy of irradiance produced by the SASHE is expected to be better than ±5%, which includes calibration and instrument stability errors. Under suitably uniform atmospheric conditions, higher calibration accuracy and precisions (±1%) can be obtained when the responsivity is tied to the solar extraterrestrial irradiance via Langley regression plots. This approach is recommended when high-precision measurements of optical depth are required.
DOI: 10.6084/m9.figshare.23255255
title: Results Meeting 25_10

description: The setup was installed in the Instron 5985 for the first time. <br> The data files only show the locking of the compaction plate, a cycle and compliance curves taken sometime after. No data was used
DOI: 10.6084/m9.figshare.23255255.v2
title: Results Meeting 25_10

description: The setup was installed in the Instron 5985 for the first time. <br> The data files only show the locking of the compaction plate, a cycle and compliance curves taken sometime after. No data was used
DOI: 10.6084/m9.figshare.23255255.v1
title: Results Meeting 25_10

description: The setup was installed in the Instron 5985 for the first time. <br> The data files only show the locking of the compaction plate, a cycle and compliance curves taken sometime after. No data was used
DOI: 10.6084/m9.figshare.23258570
title: Supplementary Material for: Key prognostic factors create a composite risk score to stratify patients into high- and low treatment benefit groups: A multicenter, retrospective data analysis of 84 mCRC patients treated with regorafenib as part of the CORRECT and CONSIGN trials

description: Introduction: In further-line mCRC treatment, median progression-free survival (PFS) is rather short, and many patients do not benefit from any anti-tumor treatment and should therefore treated according to best-supportive care (BSC). A risk score based on standard laboratory values using markers of tumor inflammation aims to define a patient cohort with high treatment benefit and might offer insights into tumor biology. As regorafenib has been dropped off the German market due to an unfavorable risk-benefit ratio, patient selection is key for any further-line treatment option. Methods: We used cox regression analysis to determine lab markers that are independent prognostic factors of OS and PFS outcome. The influence of these variables was weighted using an estimator, which was calculated using cox regression analysis. The estimators were implemented as multiplication factors, resulting in a risk score. A cut-off value for the resulting risk values was then determined via cox regression analysis resulting in a low- and high-risk subgroup. Results: Using data of 82 patients, a risk score identifying long-term survival in patients with last line mCRC treatment could be calculated. The following parameters were associated with significantly longer survival in multivariate analysis: NLR ≤ 5 (p = &lt;0.001), AP ≤200 U/L (p = 0.001), CRP ≤3.2mg/dl (p = &lt;0.001). The following estimator values were used to calculate a risk score: NLR: 0.132 (p=0.046), AP: 0.004 (p=0.014), and CRP: 0.032 (p=0.039). Implementing the estimators as multiplication factors yielded the following risk score: 0.132*NLR + 0.004*AP + 0.032*CRP = Risk value. Cox regression resulted in low- and high-risk subgroups with risk values below and above 1.4, respectively. In the group with a low-risk score (&lt;1.4), patients had a median OS of 10.5 months after initiating regorafenib. Patients with a high-risk score (&gt;1.4) survived only 3.3 months after starting therapy with regorafenib (n=43, p&lt;0.001, HR=3.76). Discussion/Conclusions: The presented composite risk score stratifies patients into two prognostic subgroups characterized by standard laboratory values. Patients with signs of systemic characterized by elevated NLR, AP, and CRP have a high composite risk score and a significant shorter overall survival. Although this score needs to be prospectively validated in larger cohorts, it may be used to stratify patients suitable for further-line treatment studies.
DOI: 10.6084/m9.figshare.23258570.v1
title: Supplementary Material for: Key prognostic factors create a composite risk score to stratify patients into high- and low treatment benefit groups: A multicenter, retrospective data analysis of 84 mCRC patients treated with regorafenib as part of the CORRECT and CONSIGN trials

description: Introduction: In further-line mCRC treatment, median progression-free survival (PFS) is rather short, and many patients do not benefit from any anti-tumor treatment and should therefore treated according to best-supportive care (BSC). A risk score based on standard laboratory values using markers of tumor inflammation aims to define a patient cohort with high treatment benefit and might offer insights into tumor biology. As regorafenib has been dropped off the German market due to an unfavorable risk-benefit ratio, patient selection is key for any further-line treatment option. Methods: We used cox regression analysis to determine lab markers that are independent prognostic factors of OS and PFS outcome. The influence of these variables was weighted using an estimator, which was calculated using cox regression analysis. The estimators were implemented as multiplication factors, resulting in a risk score. A cut-off value for the resulting risk values was then determined via cox regression analysis resulting in a low- and high-risk subgroup. Results: Using data of 82 patients, a risk score identifying long-term survival in patients with last line mCRC treatment could be calculated. The following parameters were associated with significantly longer survival in multivariate analysis: NLR ≤ 5 (p = &lt;0.001), AP ≤200 U/L (p = 0.001), CRP ≤3.2mg/dl (p = &lt;0.001). The following estimator values were used to calculate a risk score: NLR: 0.132 (p=0.046), AP: 0.004 (p=0.014), and CRP: 0.032 (p=0.039). Implementing the estimators as multiplication factors yielded the following risk score: 0.132*NLR + 0.004*AP + 0.032*CRP = Risk value. Cox regression resulted in low- and high-risk subgroups with risk values below and above 1.4, respectively. In the group with a low-risk score (&lt;1.4), patients had a median OS of 10.5 months after initiating regorafenib. Patients with a high-risk score (&gt;1.4) survived only 3.3 months after starting therapy with regorafenib (n=43, p&lt;0.001, HR=3.76). Discussion/Conclusions: The presented composite risk score stratifies patients into two prognostic subgroups characterized by standard laboratory values. Patients with signs of systemic characterized by elevated NLR, AP, and CRP have a high composite risk score and a significant shorter overall survival. Although this score needs to be prospectively validated in larger cohorts, it may be used to stratify patients suitable for further-line treatment studies.
DOI: 10.6084/m9.figshare.23258573
title: Supplementary Material for: Key prognostic factors create a composite risk score to stratify patients into high- and low treatment benefit groups: A multicenter, retrospective data analysis of 84 mCRC patients treated with regorafenib as part of the CORRECT and CONSIGN trials

description: Introduction: In further-line mCRC treatment, median progression-free survival (PFS) is rather short, and many patients do not benefit from any anti-tumor treatment and should therefore treated according to best-supportive care (BSC). A risk score based on standard laboratory values using markers of tumor inflammation aims to define a patient cohort with high treatment benefit and might offer insights into tumor biology. As regorafenib has been dropped off the German market due to an unfavorable risk-benefit ratio, patient selection is key for any further-line treatment option. Methods: We used cox regression analysis to determine lab markers that are independent prognostic factors of OS and PFS outcome. The influence of these variables was weighted using an estimator, which was calculated using cox regression analysis. The estimators were implemented as multiplication factors, resulting in a risk score. A cut-off value for the resulting risk values was then determined via cox regression analysis resulting in a low- and high-risk subgroup. Results: Using data of 82 patients, a risk score identifying long-term survival in patients with last line mCRC treatment could be calculated. The following parameters were associated with significantly longer survival in multivariate analysis: NLR ≤ 5 (p = &lt;0.001), AP ≤200 U/L (p = 0.001), CRP ≤3.2mg/dl (p = &lt;0.001). The following estimator values were used to calculate a risk score: NLR: 0.132 (p=0.046), AP: 0.004 (p=0.014), and CRP: 0.032 (p=0.039). Implementing the estimators as multiplication factors yielded the following risk score: 0.132*NLR + 0.004*AP + 0.032*CRP = Risk value. Cox regression resulted in low- and high-risk subgroups with risk values below and above 1.4, respectively. In the group with a low-risk score (&lt;1.4), patients had a median OS of 10.5 months after initiating regorafenib. Patients with a high-risk score (&gt;1.4) survived only 3.3 months after starting therapy with regorafenib (n=43, p&lt;0.001, HR=3.76). Discussion/Conclusions: The presented composite risk score stratifies patients into two prognostic subgroups characterized by standard laboratory values. Patients with signs of systemic characterized by elevated NLR, AP, and CRP have a high composite risk score and a significant shorter overall survival. Although this score needs to be prospectively validated in larger cohorts, it may be used to stratify patients suitable for further-line treatment studies.
DOI: 10.6084/m9.figshare.23258573.v1
title: Supplementary Material for: Key prognostic factors create a composite risk score to stratify patients into high- and low treatment benefit groups: A multicenter, retrospective data analysis of 84 mCRC patients treated with regorafenib as part of the CORRECT and CONSIGN trials

description: Introduction: In further-line mCRC treatment, median progression-free survival (PFS) is rather short, and many patients do not benefit from any anti-tumor treatment and should therefore treated according to best-supportive care (BSC). A risk score based on standard laboratory values using markers of tumor inflammation aims to define a patient cohort with high treatment benefit and might offer insights into tumor biology. As regorafenib has been dropped off the German market due to an unfavorable risk-benefit ratio, patient selection is key for any further-line treatment option. Methods: We used cox regression analysis to determine lab markers that are independent prognostic factors of OS and PFS outcome. The influence of these variables was weighted using an estimator, which was calculated using cox regression analysis. The estimators were implemented as multiplication factors, resulting in a risk score. A cut-off value for the resulting risk values was then determined via cox regression analysis resulting in a low- and high-risk subgroup. Results: Using data of 82 patients, a risk score identifying long-term survival in patients with last line mCRC treatment could be calculated. The following parameters were associated with significantly longer survival in multivariate analysis: NLR ≤ 5 (p = &lt;0.001), AP ≤200 U/L (p = 0.001), CRP ≤3.2mg/dl (p = &lt;0.001). The following estimator values were used to calculate a risk score: NLR: 0.132 (p=0.046), AP: 0.004 (p=0.014), and CRP: 0.032 (p=0.039). Implementing the estimators as multiplication factors yielded the following risk score: 0.132*NLR + 0.004*AP + 0.032*CRP = Risk value. Cox regression resulted in low- and high-risk subgroups with risk values below and above 1.4, respectively. In the group with a low-risk score (&lt;1.4), patients had a median OS of 10.5 months after initiating regorafenib. Patients with a high-risk score (&gt;1.4) survived only 3.3 months after starting therapy with regorafenib (n=43, p&lt;0.001, HR=3.76). Discussion/Conclusions: The presented composite risk score stratifies patients into two prognostic subgroups characterized by standard laboratory values. Patients with signs of systemic characterized by elevated NLR, AP, and CRP have a high composite risk score and a significant shorter overall survival. Although this score needs to be prospectively validated in larger cohorts, it may be used to stratify patients suitable for further-line treatment studies.
DOI: 10.5281/zenodo.7702664
title: Complementary Dataset for PACIS2023 Submission

description: Complementary Dataset for PACIS2023 Submission
DOI: 10.5281/zenodo.7979506
title: Complementary Dataset for the PACIS2023 Paper ID: 1175

description: Complementary Dataset for the PACIS2023 paper: "Creating Common Ground: Formalizing and Designing Employee-driven Innovation Processes with Decision Points"
DOI: 10.5281/zenodo.7979515
title: Complementary Dataset for the PACIS2023 Paper ID: 1175

description: Complementary Dataset for the PACIS2023 paper: "Creating Common Ground: Formalizing and Designing Employee-driven Innovation Processes with Decision Points"
DOI: 10.5281/zenodo.7702663
title: Complementary Dataset for the PACIS2023 Paper ID: 1175

description: Complementary Dataset for the PACIS2023 paper: "Creating Common Ground: Formalizing and Designing Employee-driven Innovation Processes with Decision Points"
DOI: 10.5281/zenodo.7983408
title: Complementary Dataset for the PACIS2023 Paper ID: 1175

description: Complementary Dataset for the PACIS2023 paper: "Creating Common Ground: Formalizing and Designing Employee-driven Innovation Processes with Decision Points"
DOI: 10.5519/qd.q53dqnfl
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (435 records)
DOI: 10.5281/zenodo.7955572
title: code-of-WMC

description: We will upload the code for WMC soon
DOI: 10.5281/zenodo.7955573
title: code-of-WMC

description: We will upload the code for WMC, if the paper is published.
DOI: 10.5281/zenodo.7983418
title: code-of-WMC

description: We will upload the code for WMC soon
DOI: 10.18112/openneuro.ds004551.v1.0.6
title: testMIproject
DOI: 10.6084/m9.figshare.23258636
title: Essential and non-essential element concentrations in organ tissues and feces of stranded odontocetes in the southeastern United States

description: Essential (Co, Cu, Fe, Mn, Mo, Se, Zn) and non-essential (As, Cd, Hg, Pb, Tl) element concentrations in organ tissues and feces of stranded odontocete whales in the southeastern United States
DOI: 10.6084/m9.figshare.23258636.v1
title: Essential and non-essential element concentrations in organ tissues and feces of stranded odontocetes in the southeastern United States

description: Essential (Co, Cu, Fe, Mn, Mo, Se, Zn) and non-essential (As, Cd, Hg, Pb, Tl) element concentrations in organ tissues and feces of stranded odontocete whales in the southeastern United States
DOI: 10.6084/m9.figshare.23258642
title: Original data.xlsx

description: <strong>The combination of single-cell RNA sequencing and bulk RNA sequencing analysis reveals the regulatory role of cancer stem cell marker gene CXCR4 in the growth and metastasis of gastric cancer</strong>
DOI: 10.6084/m9.figshare.23258642.v1
title: Original data.xlsx

description: <strong>The combination of single-cell RNA sequencing and bulk RNA sequencing analysis reveals the regulatory role of cancer stem cell marker gene CXCR4 in the growth and metastasis of gastric cancer</strong>
DOI: 10.5281/zenodo.7983448
title: Data for 'Evaluating WRF-GC v2.0 predictions of boundary layer and vertical ozone profiles during the 2021 TRACER-AQ campaign in Houston, Texas'

description: This repository provides observation datasets, model configuration files, model boundary conditions, model input files, and scripts used in the manuscript titled 'Evaluating WRF-GC v2.0 predictions of boundary layer and vertical ozone profiles during the 2021 TRACER-AQ campaign in Houston, Texas'.
DOI: 10.25442/hku.23256839
title: Supporting data for the PhD thesis titled Interdisciplinary investigations of the Jurassic and Cretaceous terrestrial ecosystems.zip

description: This is the supporting data for the PhD thesis titled “Interdisciplinary investigations of the Jurassic and Cretaceous terrestrial ecosystems”. These data are evidence supporting the absorption features and spectra for each amber sample from the Hailar Basin in Inner Mongolia and the age constrains for the dating sample from the western Liaoning and Inner Mongolia.These data include raw FTIR data and U-Pb analytical results for the YM-1 from the Zhalainuoer coal mine and ZL-1 from the Yimin coal field in Inner Mongolia, the Ar data corrected for decay, blank and mass discrimination (1 _ errors) of the Reshuitang dating sample from the Western Liaoning, and U-Pb data of the Jiufengshan Formation from the Naketa site, North Great Xing’an Range.
DOI: 10.25442/hku.23256839.v1
title: Supporting data for the PhD thesis titled Interdisciplinary investigations of the Jurassic and Cretaceous terrestrial ecosystems.zip

description: This is the supporting data for the PhD thesis titled “Interdisciplinary investigations of the Jurassic and Cretaceous terrestrial ecosystems”. These data are evidence supporting the absorption features and spectra for each amber sample from the Hailar Basin in Inner Mongolia and the age constrains for the dating sample from the western Liaoning and Inner Mongolia.These data include raw FTIR data and U-Pb analytical results for the YM-1 from the Zhalainuoer coal mine and ZL-1 from the Yimin coal field in Inner Mongolia, the Ar data corrected for decay, blank and mass discrimination (1 _ errors) of the Reshuitang dating sample from the Western Liaoning, and U-Pb data of the Jiufengshan Formation from the Naketa site, North Great Xing’an Range.
DOI: 10.6084/m9.figshare.23258660
title: <strong>Event study approach: The case of Airbnb and hotel stocks</strong>

description: <strong>Event study approach: The case of Airbnb and hotel stocks</strong>
DOI: 10.6084/m9.figshare.23258660.v1
title: <strong>Event study approach: The case of Airbnb and hotel stocks</strong>

description: <strong>Event study approach: The case of Airbnb and hotel stocks</strong>